140Indexed trials
canonical disease area
Schizophrenia / Psychosis
Intelligence
Schizophrenia / Psychosis intelligence: 140 indexed trials, 21 recruiting studies, 107 sponsors across 50 countries.
21Recruiting
107Sponsors
50Countries
Leading sponsors
Sumitomo Pharma America, Inc.40 recruiting
University of North Carolina, Chapel Hill40 recruiting
Eli Lilly and Company31 recruiting
Shanghai Mental Health Center32 recruiting
Rovi Pharmaceuticals Laboratories30 recruiting
AstraZeneca30 recruiting
Boehringer Ingelheim30 recruiting
GlaxoSmithKline20 recruiting
Fundación Marques de Valdecilla20 recruiting
Johns Hopkins University20 recruiting
Centre for Addiction and Mental Health21 recruiting
Chonbuk National University Hospital20 recruiting
Geographic activity
United States68trials
France15trials
Germany12trials
Spain11trials
China10trials
Canada9trials
United Kingdom9trials
Taiwan9trials
Ukraine7trials
Serbia6trials
Italy6trials
South Korea6trials
Leading interventions
Risperidone6trials
risperidone6trials
Aripiprazole5trials
Lurasidone5trials
Olanzapine4trials
olanzapine4trials
Treatment as Usual2trials
Risperidone ISM® 100 mg2trials
aripiprazole2trials
Placebo patch2trials
Quetiapine2trials
Iclepertin2trials
Methodology note
This entity is derived from structured ClinicalTrials.gov conditions and/or MeSH normalization. Counts reflect the current NeuroRisk indexed corpus and are not guaranteed exhaustive global totals.